Trial intelligence / Profile preview

Azacitidine plus durvalumab versus azacitidine alone in previously untreated higher-risk MDS or elderly AML

NL-OMON46021Phase 2Withdrawn

Sponsor

Celgene Corporation

Start

Feb 2016

Modality

PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules

Countries

1